Market Currents
Novo Nordisk (NVO -0.9%) slips after an FDA review of its basal insulin degludec gets postponed...
-
Wednesday, July 18, 2012, 2:56 PM ETNovo Nordisk (NVO -0.9%) slips after an FDA review of its basal insulin degludec gets postponed yet again. The review was pushed back to November after being delayed once before in June, as the agency continues to seek outside experts for a review. Degludec is a long-lasting insulin drug designed to compete with Sanofi's (SNY +2.5%) similar product Lantus.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
